Skip to main content

Advertisement

Log in

Skin Conditions of Baseball, Cricket, and Softball Players

  • Review Article
  • Published:
Sports Medicine Aims and scope Submit manuscript

Abstract

Each year in the United States over 80 million people participate in bat-and-ball sports, for example baseball and softball. Cricket, the world’s second most popular sport, is enjoyed by hundreds of millions of participants in such countries as India, Pakistan, Australia, New Zealand, Bangladesh, South Africa, West Indies, Sri Lanka, United Kingdom, and Zimbabwe. Although any player can develop skin disease as a result of participation in these bat-and-ball sports, competitive team athletes are especially prone to skin problems related to infection, trauma, allergy, solar exposure, and other causes. These diseases can produce symptoms that hinder individual athletic performance and participation. In this review, we discuss the diagnosis and best-practice management of skin diseases that can develop as a result of participation in baseball, softball, and cricket.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Boden BP, Tacchetti R, Mueller FO. Catastrophic injuries in high school and college baseball players. Am J Sports Med. 2004;32(5):1189–96.

    Article  PubMed  Google Scholar 

  2. International Baseball Federation. IBAF number book. 2011 [cited 2012 October 1]. http://www.ibaf.org/en/infopage-detail.aspx?id=6ce46799-80df-41f5-848b-2f10a25479ee.

  3. Tator CH. Catastrophic injuries in sports and recreation: causes and prevention: a Canadian study. Canada: University of Toronto Press; 2008.

    Google Scholar 

  4. Janda DH. The prevention of baseball and softball injuries. Clin Orthop. 2003;409(Journal Article):20.

    Google Scholar 

  5. Association NSG. Report on Sports Participation. 2011.

  6. Walker HL, Carr DJ, Chalmers DJ, et al. Injury to recreational and professional cricket players: circumstances, type and potential for intervention. Accid Anal Prev. 2010;42(6):2094–8.

    Article  PubMed  CAS  Google Scholar 

  7. Cricket Australia. National Cricket Census 2011/12. Australia; 2012.

  8. England and Wales Cricket Board. Participation. 2012 [cited 2012 December 25]. http://www.ecb.co.uk/development/get-into-cricket/participation/.

  9. Rice SG, Congeni JA. Baseball and softball. Pediatrics. 2012;129(3):e842–56.

    Article  PubMed  Google Scholar 

  10. Padmanabhan RA, Fraser TG. The emergence of methicillin-resistant Staphylococcus aureus in the community. Cleve Clin J Med. 2005;72(3):235–41.

    Article  PubMed  Google Scholar 

  11. Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol. 2007;8(5):259–70.

    Article  PubMed  Google Scholar 

  12. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(10):1373–406.

    Article  PubMed  Google Scholar 

  13. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18.

    Article  PubMed  Google Scholar 

  14. Luelmo-Aguilar J, Santandreu MS. Folliculitis: recognition and management. Am J Clin Dermatol. 2004;5(5):301–10.

    Article  PubMed  Google Scholar 

  15. Adams BB. Skin infections in athletes. Dermatol Nurs. 2008;20(1):39.

    PubMed  Google Scholar 

  16. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005;352(5):468–75.

    Article  PubMed  CAS  Google Scholar 

  17. Morgan M. Treatment of MRSA soft tissue infections: an overview. Injury. 2011;42(Journal Article):S11–S7.

    Google Scholar 

  18. Chon SY, Doan HQ, Ma R, et al. Antibiotic overuse and resistance in dermatology. Dermatol Ther. 2012;25(1):55–69.

    Article  PubMed  Google Scholar 

  19. NiRiain U. Recommended management of common bacterial skin infections. Prescriber. 2011;22(15-16):14–24.

    Article  Google Scholar 

  20. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215(4):331–40.

    Article  PubMed  CAS  Google Scholar 

  21. Koning S, Verhagen AP, van Suijlekom-Smit LW, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2003;2(Journal Article).

  22. Woodford N, Afzal-Shah M, Warner M, et al. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother. 2008;62(4):766–8.

    Article  PubMed  CAS  Google Scholar 

  23. Frithsen IL, Salgado CD. Uncomplicated skin and soft tissue infections. Manag Antimicrob Infect Dis. 2010(Journal Article):301–12.

  24. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36(2):131.

    Article  PubMed  Google Scholar 

  25. Yang ES, Tan J, Eells S, et al. Body site colonization in patients with community associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol. Infect. 2010;16(5):425–31.

  26. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA. 1988;260(18):2682–5.

    Article  PubMed  CAS  Google Scholar 

  27. Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control. 2007;35(2):106–14.

    Article  PubMed  Google Scholar 

  28. Conklin RJ. Common cutaneous disorders in athletes. Sports Med. 1990;9(2):100–19.

    Article  PubMed  CAS  Google Scholar 

  29. McDaniel WE. Tinea versicolor. Arch Dermatol. 1977;113(4):519–20.

    Article  PubMed  CAS  Google Scholar 

  30. McKeag D. Basketball. Indianapolis: Blackwell Science; 2003.

    Google Scholar 

  31. Pharis DB, Teller C, Wolf JE Jr. Cutaneous manifestations of sports participation. J Am Acad Dermatol. 1997;36(3):448–59.

    Article  PubMed  CAS  Google Scholar 

  32. Morishita N, Sei Y. Microreview of Pityriasis versicolor and Malassezia species. Mycopathologia. 2006;162(6):373–6.

    Article  PubMed  CAS  Google Scholar 

  33. Prohic A, Ozegovic L. Malassezia species isolated from lesional and non-lesional skin in patients with pityriasis versicolor. Mycoses. 2007;50(1):58–63.

    Article  PubMed  Google Scholar 

  34. Baron DA, Martin DM, Magd SA. Doping in sports and its spread to at-risk populations: an international review. World Psychiatry. 2007;6(2):118.

    PubMed  Google Scholar 

  35. Walker J, Adams B. Cutaneous manifestations of anabolic–androgenic steroid use in athletes. Int J Dermatol. 2009;48(10):1044–8.

    Article  PubMed  Google Scholar 

  36. Terney R, McLain LG. The use of anabolic steroids in high school students. Arch Pediatr Adolesc Med. 1990;144(1):99.

    Article  CAS  Google Scholar 

  37. Lorang M, Callahan B, Cummins KM, et al. Anabolic androgenic steroid use in teens: prevalence, demographics, and perception of effects. J Child Adolesc Subst Abuse. 2011;20(4):358–69.

    Article  Google Scholar 

  38. Scott MJ 3rd, Scott AM. Effects of anabolic-androgenic steroids on the pilosebaceous unit. Cutis. 1992;50(2):113–6.

    PubMed  Google Scholar 

  39. Gupta AK, Batra R, Bluhm R, et al. Pityriasis versicolor. Dermatol Clin. 2003;21(3):413–29, v–vi.

  40. Faergemann J, Fredriksson T. Tinea versicolor: some new aspects on etiology, pathogenesis, and treatment. Int J Dermatol. 1982;21(1):8–12.

    Article  PubMed  CAS  Google Scholar 

  41. Durdu M, Ilkit M. First step in the differential diagnosis of folliculitis: cytology. Crit Rev Microbiol. 2012;00:1–17.

    Google Scholar 

  42. Schwartz RA. Superficial fungal infections. Lancet. 2004;364(9440):1173–82.

    Article  PubMed  Google Scholar 

  43. Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol. 2010;146(10):1132.

    Article  PubMed  Google Scholar 

  44. Sánchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol. 1984;11(2):235–8.

    Article  PubMed  Google Scholar 

  45. Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol. 1986;15(3):500–3.

    Article  PubMed  CAS  Google Scholar 

  46. Goodless DR, Ramos-Caro FA, Flowers FP. Ketoconazole in the treatment of pityriasis versicolor: international review of clinical trials. Ann Pharmacother. 1991;25(4):395–8.

    CAS  Google Scholar 

  47. Köse O, Tastan HB, Gür AR, et al. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatol Treat. 2002;13(2):77–9.

    Article  Google Scholar 

  48. Amer MA. Fluconazole in the treatment of tinea versicolor. Int J Dermatol. 1997;36(12):940–2.

    Article  PubMed  CAS  Google Scholar 

  49. Difonzo EM. Italian multicentre study with oral itraconazole in recurrent pityriasis versicolor, preliminary report. J Eur Acad Dermatol Venereol. 1992;1(5):S19–20.

    Article  Google Scholar 

  50. Watanabe S, Harada T, Hiruma M, et al. Epidemiological survey of foot diseases in Japan: results of 30,000 foot checks by dermatologists. J Dermatol. 2010;37(5):397–406.

    Article  PubMed  Google Scholar 

  51. Kemna ME, Elewski BE. A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol. 1996;35(4):539–42.

    Article  PubMed  CAS  Google Scholar 

  52. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50(5):748–52.

    Article  PubMed  Google Scholar 

  53. English MP, Gibson MD. Studies in the epidemiology of tinea pedis. Br Med J. 1959;1(5135):1442–6.

    Article  PubMed  CAS  Google Scholar 

  54. Attye A, Auger P, Joly J. Incidence of occult athlete’s foot in swimmers. Eur J Epidemiol. 1990;6(3):244–7.

    Article  PubMed  CAS  Google Scholar 

  55. Bolanos B. Dermatophyte feet infection among students enrolled in swimming courses at a university pool. Boletin de la Asociacion Medica de Puerto Rico. 1991;83(5):181–4.

    PubMed  CAS  Google Scholar 

  56. Gentles JC, Evans EGV, Jones GR. Control of tinea pedis in a swimming bath. Br Med J. 1974;2(5919):577–80.

    Article  PubMed  CAS  Google Scholar 

  57. Adams BB. Fungal skin infections. Sports Dermatology. New York: Springer; 2006. p. 203–80.

    Google Scholar 

  58. Field LA, Adams BB. Tinea pedis in athletes. Int J Dermatol. 2008;47(5):485–92.

    Article  PubMed  Google Scholar 

  59. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Phys. 2002;65(10):2095–102.

    Google Scholar 

  60. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;3:CD001434. doi:10.1002/14651858.CD001434.pub2.

  61. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5):353–67.

    Article  PubMed  Google Scholar 

  62. De Keyser P, De Backer M, Massart DL, et al. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol. 1994;130 Suppl 43(Journal Article):22–5.

    Google Scholar 

  63. Gupta AK, Doncker PD, Heremans A, et al. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. J Am Acad Dermatol. 1997;36(5 Pt 1):789–92.

    Article  PubMed  CAS  Google Scholar 

  64. Aguila R, Montero Gei F, Robles M, et al. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis. Clin Exp Dermatol. 1992;17(6):402–6.

    Google Scholar 

  65. Odom R. Pathophysiology of dermatophyte infections. J Am Acad Dermatol. 1993;28(5 Pt 1):S2–7.

    Article  PubMed  CAS  Google Scholar 

  66. Levine N. Dermatologic aspects of sports medicine. J Am Acad Dermatol. 1980;3(4):415–24.

    Article  PubMed  CAS  Google Scholar 

  67. Beck CK. Infectious diseases in sports. Med Sci Sports Exerc. 2000;32(7):S431.

    PubMed  CAS  Google Scholar 

  68. Thomas J, Jacobson GA, Narkowicz CK, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519.

    Article  PubMed  CAS  Google Scholar 

  69. Rodríguez-Pazos L, Pereiro-Ferreirós MM, Pereiro M, et al. Onychomycosis observed in children over a 20-year period. Mycoses. 2011;54(5):450–3.

    Article  PubMed  Google Scholar 

  70. Purim KS, Bordignon GP, Queiroz-Telles F. Fungal infection of the feet in soccer players and non-athlete individuals. Rev Iberoam Micol. 2005;22(Journal Article):34–8.

    Google Scholar 

  71. Caputo R, De Boulle K, Del Rosso J, et al. Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature. J Eur Acad Dermatol Venereol. 2001;15(4):312–6.

    PubMed  CAS  Google Scholar 

  72. Zaias N. Clinical manifestations of onychomycosis. Clin Exp Dermatol. 1992;17(Journal Article):6–7.

    Google Scholar 

  73. Weinberg JM, Koestenblatt EK, Tutrone WD, et al. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol. 2003;49(2):193–7.

    Article  PubMed  Google Scholar 

  74. Szepietowski JC, Reich A, Garlowska E, et al. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol. 2006;142(10):1279.

    Article  PubMed  Google Scholar 

  75. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol. 1992;17(Suppl 1):41–3.

    Article  PubMed  Google Scholar 

  76. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150(3):537–44.

    Article  PubMed  CAS  Google Scholar 

  77. Elewski B, Pollak R, Ashton S, et al. A randomized, placebo-and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166(2):389–98.

    Article  PubMed  CAS  Google Scholar 

  78. Esterowitz D, Greer KE, Cooper PH, et al. Plantar warts in the athlete. Am J Emerg Med. 1995;13(4):441–3.

    Article  PubMed  CAS  Google Scholar 

  79. Squires S. Orioles pitcher among wart casualties. Washington Post. 1998; Sect. Z09.

  80. Roach MC, Chretien JH. Common hand warts in athletes: association with trauma to the hand. J Am Coll Health. 1995;44(3):125–6.

    Article  PubMed  CAS  Google Scholar 

  81. Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144(1):4–11.

    Article  PubMed  CAS  Google Scholar 

  82. Bunney MH, Nolan MW, Williams DA. An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol. 1976;94(6):667–79.

    Article  PubMed  CAS  Google Scholar 

  83. Parish LC, Monroe E, Rex IH Jr. Treatment of common warts with high-potency (26%) salicylic acid. Clin Ther. 1988;10(4):462–6.

    PubMed  CAS  Google Scholar 

  84. Coskey RJ. Treatment of plantar warts in children with a salicylic acid-podophyllin-cantharidin product. Pediatr Dermatol. 1984;2(1):71–3.

    Article  PubMed  CAS  Google Scholar 

  85. Phelps WC, Alexander KA. Antiviral therapy for human papillomaviruses: rationale and prospects. Ann Intern Med. 1995;123(5):368.

    Article  PubMed  CAS  Google Scholar 

  86. Muzio G, Massone C, Rebora A. Treatment of non-genital warts with topical imiquimod 5% cream. Eur J Dermatol. 2002;12(4):347–9.

    PubMed  CAS  Google Scholar 

  87. Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol. 2001;137(4):451.

    PubMed  CAS  Google Scholar 

  88. Tlougan BE, Mancini AJ, Mandell JA, et al. Skin conditions in figure skaters, ice-hockey players and speed skaters: part II—cold-induced, infectious and inflammatory dermatoses. Sports Med. 2011;41(11):967–84.

    Article  PubMed  Google Scholar 

  89. Kwok CS, Holland R, Gibbs S. Efficacy of topical treatments for cutaneous warts: a meta analysis and pooled analysis of randomized controlled trials. Br J Dermatol. 2011;165(2):233–46.

    Google Scholar 

  90. Dreazen JR, Mulhem E. Electrodesiccation and curettage for removal of nongenital warts. Am Fam Phys. 2012;85(8):e2.

    Google Scholar 

  91. Clifton MM, Johnson SM, Roberson PK, et al. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol. 2003;20(3):268–71.

    Article  PubMed  Google Scholar 

  92. Horn TD, Johnson SM, Helm RM, et al. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol. 2005;141(5):589.

    Article  PubMed  Google Scholar 

  93. Rutala W, Weber DJ. Guidelines for disinfection and sterilization in healthcare facilities. Atlanta: Center for Disease Control; 2008.

    Google Scholar 

  94. Knapik JJ, Reynolds KL, Duplantis KL, et al. Friction blisters. Pathophysiology, prevention and treatment. Sports Med. 1995;20(3):136–47.

    Article  PubMed  CAS  Google Scholar 

  95. Akers WA, Sulzberger MB. The friction blister. Plast Reconstr Surg. 1972;50(1):98.

    Google Scholar 

  96. Brennan FH Jr. Managing blisters in competitive athletes. Curr Sports Med Rep. 2002;1(6):319–22.

    PubMed  Google Scholar 

  97. Pecci M, Comeau D, Chawla V. Skin conditions in the athlete. Am J Sports Med. 2009;37(2):406–18.

    Article  PubMed  Google Scholar 

  98. Fine JD, Eady RA, Bauer EA, et al. Revised classification system for inherited epidermolysis bullosa: Report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol. 2000;42(6):1051–66.

    Article  PubMed  CAS  Google Scholar 

  99. Chun YI, Jang IS, Park SS, et al. A case of epidermolysis bullosa (Weber-Cockayne Type). Korean J Dermatol. 1985;23(4):503–6.

    Google Scholar 

  100. Cortese TA Jr, Fukuyama K, Epstein W, et al. Treatment of friction blisters: an experimental study. Arch Dermatol. 1968;97(6):717.

    Article  PubMed  Google Scholar 

  101. Hoeffler DF. Friction blisters and cellulitis in a navy recruit population. Mil Med. 1975;140(5):333–7.

    PubMed  CAS  Google Scholar 

  102. Adams BB. Friction injuries to the skin. Sports Dermatology. New York: Springer; 2006. p. 203–40.

    Google Scholar 

  103. Mailler EA, Adams BB. The wear and tear of 26.2: dermatological injuries reported on marathon day. Br J Sports Med. 2004;38(4):498–501.

    Article  PubMed  CAS  Google Scholar 

  104. Inui S, Yamamoto S, Ikegami R, et al. Baseball pitcher’s friction dermatitis. Contact Dermat. 2002;47(3):176–7.

    Article  CAS  Google Scholar 

  105. Uchiyama M, Tsuboi R, Mitsuhashi Y. Athlete’s nodule. J Dermatol. 2009;36(11):608–11.

    Article  PubMed  Google Scholar 

  106. Cohen PR, Eliezri YD, Silvers DN. Athlete’s nodules: sports-related connective tissue nevi of the collagen type (collagenomas). Cutis. 1992;50(2):131–5.

    PubMed  CAS  Google Scholar 

  107. Erickson JG, von Gemmingen GR. Surfer’s nodules and other complications of surfboarding. JAMA. 1967;201(2):134–6.

    Article  PubMed  CAS  Google Scholar 

  108. Paller AS, Hebert AA. Knuckle pads in children. Arch Pediatr Adolesc Med. 1986;140(9):915.

    Article  CAS  Google Scholar 

  109. Adams BB. Sports dermatology: prevention. In: Norman R, editor. Preventive dermatology. London: Springer; 2010. p. 161–71.

    Google Scholar 

  110. Borelli C, Bielfeldt S, Borelli S, et al. Cream or foam in pedal skin care: towards the ideal vehicle for urea used against dry skin. Int J Cosmet Sci. 2011;33(1):37–43.

    Article  PubMed  CAS  Google Scholar 

  111. Ademola J. Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis. Am J Clin Dermatol. 2002;3(Journal Article):217–22.

    Google Scholar 

  112. Akdemir O, Bilkay U, Tiftikcioglu YO, et al. New alternative in treatment of callus. J Dermatol. 2011;38(2):146–50.

    Article  PubMed  Google Scholar 

  113. Singh D, Bentley G, Trevino SG. Callosities, corns, and calluses. Br Med J. 1996;312(7043):1403.

    CAS  Google Scholar 

  114. Bae JM, Kang H, Kim HO, et al. Differential diagnosis of plantar wart from corn, callus and healed wart with the aid of dermoscopy. Br J Dermatol. 2009;160(1):220–2.

    Article  PubMed  CAS  Google Scholar 

  115. Basler RS. Acne mechanica in athletes. Cutis. 1992;50(2):125–8.

    PubMed  CAS  Google Scholar 

  116. Cordoro K, Ganz J. Training room management of medical conditions: sports dermatology. Clin Sports Med. 2005;24(3):565–98. (viii).

    Article  PubMed  Google Scholar 

  117. Fitzpatrick TB, Wolff K. Fitzpatrick’s dermatology in general medicine. New York: McGraw–Hill Medical; 2008.

    Google Scholar 

  118. Basler RSW. Skin injuries in sports medicine. J Am Acad Dermatol. 1989;21(6):1257–62.

    Article  PubMed  CAS  Google Scholar 

  119. Birrer RB, Griesemer B, Cataletto MB. Pediatric sports medicine for primary care. Philadelphia: Lippincott Williams & Wilkins; 2002.

    Google Scholar 

  120. Tlougan BE, Mancini AJ, Mandell JA, et al. Skin conditions in figure skaters, ice-hockey players and speed skaters: part I—mechanical dermatoses. Sports Med. 2011;41(9):709–19.

    Article  PubMed  Google Scholar 

  121. Urbina F, Leon L, Sudy E. Black heel, talon noir or calcaneal petechiae? Australas J Dermatol. 2008;49(3):148–51.

    Article  PubMed  Google Scholar 

  122. Zalaudek I, Argenziano G, Soyer HP, et al. Dermoscopy of subcorneal hematoma. Dermatol Surg. 2004;30(9):1229–32.

    Article  PubMed  Google Scholar 

  123. Mailler-Savage EA, Adams BB. Skin manifestations of running. J Am Acad Dermatol. 2006;55(2):290–301.

    Article  PubMed  Google Scholar 

  124. Adams BB. Jogger’s toenail. J Am Acad Dermatol. 2003;48(5):S58–9.

    Article  PubMed  Google Scholar 

  125. Colver GB, Ryan TJ. Acquired port-wine stain. Arch Dermatol. 1986;122(12):1415–6.

    Article  PubMed  CAS  Google Scholar 

  126. Adams BB, Lucky AW. Acquired port-wine stains and antecedent trauma: case report and review of the literature. Arch Dermatol. 2000;136(7):897–9.

    Article  PubMed  CAS  Google Scholar 

  127. Rosen S, Smoller BR. Port-wine stains: a new hypothesis. J Am Acad Dermatol. 1987;17(1):164–6.

    Article  PubMed  CAS  Google Scholar 

  128. Lanigan S. Acquired port wine stains: clinical and psychological assessment and response to pulsed dye laser therapy. Br J Dermatol. 1997;137(1):86–90.

    Article  PubMed  CAS  Google Scholar 

  129. Aalto-Korte K, Välimaa J, Henriks-Eckerman ML, et al. Allergic contact dermatitis from salicyl alcohol and salicylaldehyde in aspen bark (Populus tremula). Contact Dermat. 2005;52(2):93–5.

    Article  CAS  Google Scholar 

  130. Acebo E, Ratón JA, Sautúa S, et al. Allergic contact dermatitis from Boswellia serrata extract in a naturopathic cream. Contact Dermat. 2004;51(2):91–2.

    Article  Google Scholar 

  131. Akyol A, Boyvat A, Kundakci N. Contact sensitivity to aluminum. Int J Dermatol. 2004;43(12):942–3.

    Article  PubMed  CAS  Google Scholar 

  132. Corazza M, Zauli S, Pagnoni A, et al. Allergic contact dermatitis caused by metals in blackboard chalk: a case report. Acta Derm Venereol. 2012;92(4):436–7.

    Article  PubMed  Google Scholar 

  133. Curley RK, Macfarlane AW, King CM. Contact sensitivity to the amide anesthetics lidocaine, prilocaine, and mepivacaine: case report and review of the literature. Arch Dermatol. 1986;122(8):924.

    Article  PubMed  CAS  Google Scholar 

  134. Downs AMR, Sansom JE. Colophony allergy: a review. Contact Dermat. 1999;41(6):305–10.

    Article  CAS  Google Scholar 

  135. Frangella C, Chiaradia G, Rizzi A, et al. Allergic risk in sport: public health issues. Sport Sci Health. 2011;6(2):77–84.

    Article  Google Scholar 

  136. Gan SL, Goh CL, Lee CS, et al. Occupational dermatosis among sanders in the furniture industry. Contact Dermat. 1987;17(4):237–40.

    Article  CAS  Google Scholar 

  137. Kockentiet B, Adams BB. Contact dermatitis in athletes. J Am Acad Dermatol. 2007;56(6):1048–55.

    Article  PubMed  Google Scholar 

  138. Park HJ, Kang HA, Lee JY, et al. Allergic contact dermatitis from benzalkonium chloride in an antifungal solution. Contact Dermat. 2000;42(5):306–7.

    CAS  Google Scholar 

  139. Smith RG. Shoe dermatitis: a review of current concepts. Foot. 2008;18(1):40–7.

    Article  Google Scholar 

  140. Steinkjer B, Braathen LR. Contact dermatitis from triclosan (Irgasan DP 300). Contact Dermat. 1988;18(4):243–4.

    Article  CAS  Google Scholar 

  141. Tan KS, Mitchell JC. Patch and photopatch tests in contact dermatitis and photodermatitis: a preliminary report of investigation of 150 patients, with special reference to “cedar-poisoning”. Can Med Assoc J. 1968;98(5):252.

    PubMed  CAS  Google Scholar 

  142. Vokoun FJ. Linseed oil dermatitis. JAMA. 1927;89(1):20.

    Article  Google Scholar 

  143. Zug KA, Warshaw EM, Fowler JF Jr, et al. Patch-test results of the North American contact dermatitis group 2005–2006. Dermatitis. 2009;20(3):149.

    PubMed  CAS  Google Scholar 

  144. Beltrani VS. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol. 1999;104(3, supplement):S87–98.

    Article  PubMed  CAS  Google Scholar 

  145. Weston WL, Bruckner A. Allergic contact dermatitis. Pediatr Clin N Am. 2000;47(4):897–907.

    Article  CAS  Google Scholar 

  146. Emmett EA, Risby TH, Taylor J, et al. Skin elicitation threshold of ethylbutyl thiourea and mercaptobenzothiazole with relative leaching from sensitizing products. Contact Dermat. 1994;30(2):85–90.

    Article  CAS  Google Scholar 

  147. Shackelford KE, Belsito DV. The etiology of allergic-appearing foot dermatitis: A 5-year retrospective study. J Am Acad Dermatol. 2002;47(5):715–21.

    Article  PubMed  Google Scholar 

  148. Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy. Dermatology. 1989;179(2):67–72.

    Article  CAS  Google Scholar 

  149. Commens C, McGeogh A, Bartlett B, et al. Bindii (Jo Jo) dermatitis (Soliva pterosperma [Compositae]). J Am Acad Dermatol. 1984;10(5 Pt 1):768–73.

    Article  PubMed  CAS  Google Scholar 

  150. Commens CA, Bartlett BH, McGeoch AH, et al. Bindii (jo-jo) dermatitis the clinical and histopathological spectrum. Australas J Dermatol. 1982;23(3):110–5.

    Article  PubMed  CAS  Google Scholar 

  151. Hogan PA. Bindii dermatitis. Australas J Dermatol. 1997;38(4):224–5.

    Article  PubMed  CAS  Google Scholar 

  152. Mitchell GJ. Report to the commissioner of baseball of an independent investigation into the illegal use of steroids and other performance enhancing substances by players in major league baseball: Office of the Commissioner of Baseball New York; 2007.

  153. O’Sullivan AJ, Kennedy MC, Casey JH, et al. Anabolic-androgenic steroids: medical assessment of present, past and potential users. Med J Aust. 2000;173(6):323–7.

    PubMed  Google Scholar 

  154. Scott MJ Jr, Scott MJ 3rd. Dermatologists and anabolic-androgenic drug abuse. Cutis. 1989;44(1):30.

    PubMed  Google Scholar 

  155. Maravelias C, Dona A, Stefanidou M, et al. Adverse effects of anabolic steroids in athletes: a constant threat. Toxicol Lett. 2005;158(3):167–75.

    Article  PubMed  CAS  Google Scholar 

  156. Kuhn CM. Anabolic steroids. Recent Prog Horm Res. 2002;57(1):411–34.

    Article  PubMed  CAS  Google Scholar 

  157. Green GA. Doping control for the team physician. Am J Sports Med. 2006;34(10):1690–8.

    Article  PubMed  Google Scholar 

  158. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534–42.

    Article  PubMed  Google Scholar 

  159. British Medical Journal. Best practice guidelines: anabolic steroid abuse. 2012 [cited 2012 Web Page]. http://bestpractice.bmj.com/best-practice/monograph/987/basics.html.

  160. Kang S. Topical tretinoin therapy for management of early striae. J Am Acad Dermatol. 1998;39(2):S90–2.

    Article  PubMed  CAS  Google Scholar 

  161. Fox JL. Pulse dye laser eliminates stretch marks. Cosmet Derm. 1997;10(Journal Article):51–2.

    Google Scholar 

  162. Goldman A, Rossato FAV, Prati C. Stretch marks: treatment using the 1,064-nm Nd: YAG laser. Dermatol Surg. 2008;34(5):686–92.

    Article  PubMed  CAS  Google Scholar 

  163. Hernández-Pérez E, Colombo-Charrier E, Valencia-Ibiett E. Intense pulsed light in the treatment of striae distensae. Dermatol Surg. 2002;28(12):1124–30.

    Article  PubMed  Google Scholar 

  164. Hunter MH, Carek PJ. Evaluation and treatment of women with hirsutism. Am Fam Phys. 2003;67(12):2565–72.

    Google Scholar 

  165. Melville SK, Rosenthal FS, Luckmann R, et al. Quantitative ultraviolet skin exposure in children during selected outdoor activities. Photodermatol Photoimmunol Photomed. 1991;8(3):99–104.

    PubMed  CAS  Google Scholar 

  166. Han A, Maibach HI. Management of acute sunburn. Am J Clin Dermatol. 2004;5(1):39–47.

    Article  PubMed  Google Scholar 

  167. American Academy of Dermatology. Sunscreens. 2012 [cited 2012 Web Page]. http://www.aad.org/media-resources/stats-and-facts/prevention-and-care/sunscreens.

Download references

Acknowledgments

The authors have received no funding for this article and have no conflicts of interest to declare. No other persons assisted with the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brook E. Tlougan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farhadian, J.A., Tlougan, B.E., Adams, B.B. et al. Skin Conditions of Baseball, Cricket, and Softball Players. Sports Med 43, 575–589 (2013). https://doi.org/10.1007/s40279-013-0022-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40279-013-0022-4

Keywords

Navigation